# Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

> **NCT00503490** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 40 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** MP-376 (Levofloxacin solution for Inhalation)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00503490
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503490, "Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00503490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*